Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2016 Jun;30(3):609-17. doi: 10.1016/j.hoc.2016.01.005.

Pathogen Inactivation Technologies: The Advent of Pathogen-Reduced Blood Components to Reduce Blood Safety Risk.

Author information

1
Centre for Blood Research, University of British Columbia, 2350 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada; Canadian Blood Services, 1800 Alta Vista Dr., Ottawa, ON K1G 4J5, Canada. Electronic address: ddevine@pathology.ubc.ca.
2
Centre for Blood Research, University of British Columbia, 2350 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada; Canadian Blood Services, 2350 Health Sciences Mall, Vancouver, BC V6T1Z3, Canada.

Abstract

Pathogen inactivation technologies represent a shift in blood safety from a reactive approach to a proactive protective strategy. Commercially available technologies demonstrate effective killing of most viruses, bacteria, and parasites and are capable of inactivating passenger leukocytes in blood products. The use of pathogen inactivation causes a decrease in the parameters of products that can be readily measured in laboratory assays but that do not seem to cause any alteration in hemostatic effect of plasma or platelet transfusions. Effort needs to be made to further develop these technologies so that the negative quality impact is ameliorated without reducing the pathogen inactivation effectiveness.

KEYWORDS:

Blood safety; Blood transfusion; Pathogen inactivation; Pathogen reduction technology

PMID:
27112999
DOI:
10.1016/j.hoc.2016.01.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center